BERKELEY BIOSCIENCES - Key Persons
Job Titles:
- Infectious Disease Specialist / Kaiser Permanente
Job Titles:
- Clinical Professor, Co - Director of the Hepatobiliary
Dr. Bob Eghbalieh, Clinical Professor, Co-Director of the Hepatobiliary and Gastrointestinal Oncology Program and Chairman of the Cancer Committee, UCSF Fresno is a pioneer in the studies of Diindolylmethane in hepatobiliary and gastrointestinal oncology patients. He has and continues to do pioneering research in the emerging field of clinical nutrition for cancer patients. A surgeon specializing in Hepatobiliary Pancreatic Surgery and Robotic Surgery techniques, Dr. Eghbanlieh has a passion for holistic approaches to patient care that includes customized clinical nutrition programs for cancer patients. He has studied the application of diindolylmethane within the clinical nutrition regimens of HPB and GI oncology patients and continues to conduct pioneering research in this field. Dr. Eghbalieh will be heading many of the double-blind human clinical trials of the Berkeley Immune Support Formula for cancer patients in the near future. During his tenure at UCSF Fresno, he has served in many roles including: Vice Chair of Surgery, Director of Robotic Surgery, Co-Director of the HPB and GI Oncology, the Cancer Liaison Physician (CLP) to the Commission on Cancer, the Chair of Cancer Committee, as well as the Chairman of the Executive Committee at Community Medical Centers (CMC) in Fresno, California. Over the years he has accumulated numerous accolades including: Best Laparoscopic Surgeon in Fresno 2011, American Cancer Society's 2012 "Physician Innovation Award" for his work with Pancreatic Cancer patients, Leukemia Lymphoma Society's "2015 Man of Year for Central California", as well as "Outstanding Leadership Award" 2009-2017 for his role in the CMC Cancer Committee. Dr. Eghbalieh is a member of the American Medical Association and the Fresno-Madera County Medical Association. He is a Fellow of the American College of Surgery (FACS), American Pancreatic Association, American Hepato-Pancreato-Biliary Association, Society of American Gastrointestinal Endoscopic Surgeons (SAGES), California Medical Association, American College of Physician Executives, Clinical Robotics Surgery Association and the American Society of Peritoneal Surface Malignancies. Dr. Eghbalieh is a member of the Scientific Advisory Board of Berkeley BioSciences, Inc.
Dr. Christopher Benz, M.D., is Professor of Medicine in Oncology at the University of California San Francisco School of Medicine and Program Director of the Cancer and Developmental Therapeutics Program at the Buck Institute for Research on Aging. He is an internationally recognized scientist in cancer research. When he joined the UCSF Medical Center in 1983, he established the very first laboratory at UCSF focused on breast cancer research. He is a practicing oncologist at the UCSF Carol Franc Buck Breast Care Center, senior member of the UCSF Cancer Center Breast Oncology Program, faculty member in the UCSF-UC Berkeley Graduate Program of Bioengineering, and a member of the American Association for Cancer Research International Aging Taskforce. Dr. Benz is a key participant in the interdisciplinary team of Buck Institute geroscientists actively collaborating to better understand and prevent age-associated illnesses like cancer. A primary goal of Dr. Benz's research has been to understand the link between aging and cancer: why the incidence of cancer increases with age, how the biology of cancer is impacted by normal aging, and how to use this information to improve cancer prevention and treatment. The Benz laboratory at the Buck Institute focuses on several clinical types of breast cancer including those that over-express the estrogen receptor (ER), an age-associated mechanism that drives the most rapidly increasing form of breast cancer worldwide. Dr. Benz has published over 100 publications in prominent scientific journals and actively collaborates with the laboratory of Dr. Firestone at UC Berkeley in the research of Diindolylmethane. Dr. Benz is a member of the Scientific Advisory Board of Berkeley BioSciences, Inc.
Job Titles:
- Director of the National Institute
Dr. Gary Firestone, Ph.D., is Director of the National Institutes of Health Cancer Research Program, Professor of Molecular and Cell Biology, and former Chairman of the College of Letters and Science at the University of California at Berkeley. He is an internationally recognized scientist in the field of molecular oncology and a highly sought after speaker at scientific conferences on oncology research. His laboratory is also recognized for its pioneering work on Diindolylmethane. Dr. Firestone's laboratory, in collaboration Dr. Bjeldanes' laboratory, was the first in the world to conduct a human clinical study on Diindolylmethane supplementation and demonstrate that it increased the 2-hydroxylation of estrogen metabolites-a very important biological process that promotes healthy aging in women. Together, Dr. Firestone and Dr. Bjeldanes as a team have published more scientific papers on Diindolymethane and its precursor compound, Indole-3-Carbinol, than any other scientific team in the world. Dr. Firestone has published over 100 publications in prominent scientific journals and is the inventor of multiple issued and pending patents in the fields of molecular immunology, oncology and nutrition. Dr. Firestone has served on the Editorial Boards of the Journal of Molecular Endocrinology and the Journal of Experimental Zoology in addition to serving on the grant review boards of the National Science Foundation and the National Institutes of Health. He is a member of the American Society of Cell Biology, American Association of Cancer Research and the American Association for the Advancement of Science. Dr. Firestone is a co-founder of Berkeley BioSciences, Inc. and a member of its Scientific Advisory Board.
Job Titles:
- Director of Gynecologic Oncology
- Professor
Dr. Giuseppe Del Priore, M.D., M.P.H. is Professor of Medicine and Director of Gynecologic Oncology at the Indiana University School of Medicine. Prior to joining the faculty at Indiana University School of Medicine, Dr. Del Priore was the Vice President of Research at the New York University Downtown Hospital where he supervised human clinical trials of Diindolylmethane. Dr. Del Priore's current research efforts continue to focus on Diindolylmethane as a naturally occurring nutrient that can confer significant health benefits within clinical settings. Additinoally, an active area of research in Dr. Del Priore's laboratory involves the prevention of HPV infection and early treatment of this condition. Cervical dysplasia caused by HPV is currently the leading cause of cervical cancer in women worldwide and addressing cervical dysplasia early on can significantly impact the occurrence of cervical cancer worldwide. Dr. Del Priore is an Honorary member of the European Society of Gynecologic Oncology and Consultant at the Chelsea and Westminster Hospital, National Health Service, London-only one of two physicians ever to hold that honorary position. Dr. Del Priore is a member of the Scientific Advisory Board of Berkeley BioSciences, Inc.
Job Titles:
- Professor Emeritus and Former Chairman of the Nutritional Sciences Department at the University of California
Dr. Leonard Bjeldanes, Ph.D., is Professor Emeritus and former Chairman of the Nutritional Sciences Department at the University of California at Berkeley. Dr. Bjeldanes' laboratory is recognized globally for its innovations in the fields of nutrition and molecular oncology and is particularly credited for its pioneering research on Diindolylmethane (DIM). In collaboration with the laboratory of Dr. Gary Firestone at UC Berkeley, Dr. Bjeldane's laboratory is widely recognized to have identified most of the key biological mechanisms of action of Diindolylmethane. Together and in collaboration the laboratories of Dr. Bjaldenes and Dr. Firestone at UC Berkeley have published more scientific studies on Diindolylmethane and its precursor compound Indole-3-Carbinol than any other scientific team in the world. Dr. Bjeldanes has authored over 100 publications in prominent scientific journals and is the inventor of numerous issued and pending patents in the fields of molecular immunology, oncology and nutrition. Dr. Bjeldanes is a member of the American Chemical Society, American Association for the Advancement of Science, American Institute of Nutrition and the Society of Toxicology. He has served on the Editorial Boards of the Journal of Nutrition, Journal of Toxicology and Environmental Health, Food Research International and Chemical Research in Toxicology. Dr. Bjeldanes is a co-founder of Berkeley BioSciences, Inc. and served on the company's Scientific Advisory Board from 2005 through 2018, when he retired from the University and all private sector advisory boards. Professor Bjeldanes still consults with the company on projects pertaining to Diindolylmethane research while spending more time with family and hiking in the Sierra Nevada mountains in Northern California. Berkeley BioSciences is grateful for Professor Bjeldanes' years of contributions to the company and to the scientific research efforts on Diindolylmethane that he led at UC Berkeley for over 30 years.